GlassScriptPhysician profile
Nancy Ann Deeb
NPI 1629435631
$17,357.23
in general payments reported to CMS, 2019-2025
60 companies · $2,331 in 2025
The $2,331 reported for 2025 was more than what 93% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $4,890 · 2022: $4,297 · 2023: $3,387 · 2024: $2,452 · 2025: $2,331.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,012 · Education: $158.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,011.89 |
| Education | $158.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $2,738.46 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Abbvie INC. | $2,640.61 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $2,175.13 | 2021-2025 | Farxiga, Breztri, Airsupra |
| Lilly USA, LLC | $1,021.99 | 2021-2025 | Mounjaro, Jardiance, Emgality |
| Pfizer INC. | $893.46 | 2021-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $831.85 | 2021-2025 | Jardiance, Synjardy, Stiolto Respimat |
| Sanofi-Aventis U.S. LLC | $637.31 | 2021-2023 | |
| Glaxosmithkline, LLC. | $547.86 | 2021-2023 | Trelegy Ellipta, Shingrix, Arexvy |
| Janssen Pharmaceuticals, INC | $355.94 | 2021-2025 | Spravato, Xarelto |
| Scilex Pharmaceuticals INC. | $340.33 | 2021-2024 | Ztlido |
| Merck Sharp & Dohme LLC | $327.27 | 2021-2023 | Verquvo, Belsomra, Steglatro |
| Amgen INC. | $323.01 | 2021-2025 | Repatha, Otezla, Otezla |
| Biohaven Pharmaceuticals, INC. | $309.32 | 2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $307.78 | 2022 | |
| Abbott Laboratories | $280.71 | 2022-2025 | Freestyle Libre 3 |
Show all 60 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Esperion Therapeutics, INC. | $270.09 | 2021-2022 | |
| Supernus Pharmaceuticals, INC. | $253.32 | 2023-2025 | Qelbree, Qelbree |
| Vanda Pharmaceuticals INC. | $240.87 | 2024-2025 | Fanapt, Hetlioz |
| Axsome Therapeutics, INC. | $210.47 | 2024-2025 | Auvelity, Sunosi |
| Lundbeck LLC | $209.97 | 2023-2025 | Rexulti |
| Teva Pharmaceuticals USA, INC. | $187.86 | 2021-2023 | Austedo |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $176.43 | 2023-2025 | Caplyta |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $176.39 | 2021-2024 | Xifaxan |
| Astellas Pharma US INC | $150.67 | 2023-2025 | Veozah |
| Impel Pharmaceuticals INC. | $149.88 | 2023 | Trudhesa |
| Amarin Pharma, INC. | $149.76 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $138.63 | 2021-2025 | |
| Daiichi Sankyo INC. | $127.04 | 2021-2025 | Injectafer |
| Biogen, INC. | $104.96 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $86.35 | 2022-2023 | |
| Corium, LLC | $81.99 | 2023 | Adlarity |
| Paratek Pharmaceuticals, INC. | $79.02 | 2021-2024 | Nuzyra |
| Medtronic, INC. | $68.96 | 2023-2025 | Intellis Adaptivestim, Minimed 780g |
| Currax Pharmaceuticals LLC | $63.80 | 2021-2023 | Contrave |
| Hikma Pharmaceuticals USA | $55.13 | 2021-2022 | |
| Phathom Pharmaceuticals, INC. | $53.60 | 2024 | Voquezna |
| Idorsia Pharmaceuticals US INC | $52.60 | 2022-2023 | Quviviq |
| Insulet Corporation | $52.59 | 2024-2025 | Omnipod |
| Exact Sciences Corporation | $47.60 | 2023-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Otsuka America Pharmaceutical, INC. | $44.83 | 2022-2025 | Rexulti |
| Vivus LLC | $37.09 | 2022 | |
| Almatica Pharma LLC | $36.93 | 2024 | Loreev Xr |
| Eyevance Pharmaceuticals LLC | $33.43 | 2021 | |
| Cardiovascular Systems INC. | $27.05 | 2022 | |
| Upsher-Smith Laboratories LLC | $24.48 | 2021 | |
| Nabriva Therapeutics, Plc | $23.82 | 2021-2022 | |
| Xeris Pharmaceuticals, INC. | $19.06 | 2025 | Recorlev |
| Evoke Pharma, INC. | $18.69 | 2024 | |
| Verona Pharma, INC. | $17.51 | 2025 | Ohtuvayre |
| Ibsa Pharma INC. | $17.24 | 2021 | |
| Acorda Therapeutics, INC | $16.54 | 2023 | Ampyra, Inbrija |
| Tolmar, INC. | $15.31 | 2025 | Jatenzo |
| Corcept Therapeutics | $15.17 | 2021 | |
| Antares Pharma, INC. | $14.89 | 2022 | |
| Neurocrine Biosciences, INC. | $14.65 | 2022 | |
| Dexcom, INC. | $14.49 | 2022 | |
| Abiomed | $14.44 | 2025 | |
| Eisai INC. | $13.76 | 2021 | |
| Horizon Therapeutics Plc | $13.54 | 2021 | |
| Genentech USA, INC. | $5.30 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nancy Deeb listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.